Evaluating Targeted Next-Generation Sequencing (NGS) Assays and Reference Materials for NTRK Fusion Detection

Neurotrophic tyrosine receptor kinase (NTRK1/2/3) gene fusions are oncogenic drivers in ∼0.3% of solid tumors. High-quality testing to identify patients with NTRK fusion-positive tumors who could benefit from TRK inhibitors is recommended, but the current NTRK testing landscape, including next-generation sequencing (NGS), is fragmented and availability of assays varies widely.The ana lytical and clinical performance of four commonly available RNA-based NGS assays, Archer’s FusionPlex Lung panel (AFL), Illumina’s TruSight Oncology 500 (TSO500), as well as Thermo Fisher’s Oncomine Precision Assay (OPA) and Oncomine Focus Assay (OFA) were evaluated.

Source: Journal of Molecular Diagnostics - October 14, 2021 Category: Pathology Authors: Christina Bormann Chung, Jeeyun Lee, Marc Barritault, Pierre-Paul Bringuier, Zhaolin Xu, Weei-Yuarn Huang, Andrea Beharry, Joseph Castillo, Jason Christiansen, Jennifer C. Lin, Brandon S. Sheffield Source Type: research